LEVEMIR FLEXTOUCH
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Levemir FlexTouch is a long-acting basal insulin analog (insulin detemir) administered via subcutaneous injection for type 1 and type 2 diabetes management. It provides steady, peakless insulin coverage over 24 hours, reducing hypoglycemia risk compared to older insulin formulations. The FlexTouch delivery device offers patient convenience and improved adherence through its pre-filled, disposable pen design.
$184MPart D
LOE ApproachingApproaching loss of exclusivity with moderate Part D spend signals transition from growth to defensive strategies; team focus shifting toward retention and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
$184M Medicare spend — this is a commercially significant brand
Worked on LEVEMIR FLEXTOUCH at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.